Pricing Log in Create free account

Cabaletta Bio, Inc. (CABA) vs Prelude Therapeutics Incorporated (PRLD)

Cabaletta Bio, Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Cabaletta Bio, Inc. and Prelude Therapeutics Incorporated are of similar size ($265.0M and $262.8M). Cabaletta Bio, Inc. has the higher net margin (0.00% vs −269.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Cabaletta Bio, Inc. leads on 6 and Prelude Therapeutics Incorporated on 6.

Valuation

Metric CABA PRLD Biotechnology median
P/E n/m n/m 8.50
P/S n/m 14.30 9.71
P/B 1.01 2.40 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.07 n/m 0.64
EV/Sales n/m 7.54 9.21
Earnings yield (111.35%) (22.39%) (33.15%)
Free cash flow yield (72.80%) (10.39%) (25.50%)

Profitability

Metric CABA PRLD Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (300.56%) 0.00%
Net margin 0.00% (269.75%) 0.00%
Free cash flow margin 0.00% (148.30%) 0.00%
Return on equity (93.20%) (57.73%) (56.36%)
Return on assets (75.36%) (39.76%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CABA PRLD Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 10.26% 23.21% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CABA PRLD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.79 4.07 4.72
Net debt to EBITDA 0.84 1.00 0.96

Dividend

Metric CABA PRLD Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CABA PRLD Biotechnology median
Market cap 262.79m 264.95m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack